Your browser doesn't support javascript.
loading
The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients
The Korean Journal of Internal Medicine ; : 233-237, 2009.
Artículo en Inglés | WPRIM | ID: wpr-150686
ABSTRACT
BACKGROUND/

AIMS:

The efficacy and safety of a combination of ezetimibe and low-dose statin as primary treatment for dyslipidemia in renal transplant patients were evaluated prospectively.

METHODS:

The study enrolled 77 renal transplant recipients with dyslipidemia. They were given ezetimibe (10 mg) and simvastatin (10 mg) for 6 months as the initial treatment for dyslipidemia. Efficacy and safety were evaluated using lipid profiles, trough calcineurin inhibitor levels, allograft function, and adverse effects. The effects on proteinuria and high sensitivity C-reactive protein (hsCRP) levels were also evaluated.

RESULTS:

Ezetimibe and low-dose simvastatin significantly decreased the levels of total cholesterol (34.6%), triglyceride (16.0%), and low-density lipoprotein cholesterol (LDL-C) (47.6%), and 82.5% of the patients reached the target LDL-C level of <100 mg/dL. No significant change in the trough calcineurin inhibitor levels or allograft function occurred, and no serious adverse effects were observed. Fourteen patients (18.2%) discontinued treatment; eight patients (11.7%) developed muscle pain or weakness without an increase in creatinine kinase levels, and two patients (2.6%) developed elevated liver transaminase levels. The proteinuria and hsCRP levels did not change significantly.

CONCLUSIONS:

Ezetimibe and low-dose statin treatment is safe and effective as a primary treatment for dyslipidemia in renal transplant patients.
Asunto(s)

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Azetidinas / Proteína C-Reactiva / Estudios Prospectivos / Trasplante de Riñón / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Simvastatina / Dislipidemias / LDL-Colesterol Tipo de estudio: Estudio observacional Límite: Adulto / Femenino / Humanos / Masculino Idioma: Inglés Revista: The Korean Journal of Internal Medicine Año: 2009 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Azetidinas / Proteína C-Reactiva / Estudios Prospectivos / Trasplante de Riñón / Inhibidores de Hidroximetilglutaril-CoA Reductasas / Simvastatina / Dislipidemias / LDL-Colesterol Tipo de estudio: Estudio observacional Límite: Adulto / Femenino / Humanos / Masculino Idioma: Inglés Revista: The Korean Journal of Internal Medicine Año: 2009 Tipo del documento: Artículo